Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women

Fertility and Sterility

Volumn 92, Issue 3, 2009, Pages 1045-1052

  Lindsay, Robert ^a   Gallagher, J Christopher ^b   Kagan, Risa ^c   Pickar, James H ^d   Constantine, Ginger ^d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Foundation for Osteoporosis Research and Education Oakland   (United States)

^d PFIZER INC   (United States)

Author keywords

Bazedoxifene; bone mineral density; conjugated estrogens; osteoporosis; tissue selective estrogen complex

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BAZEDOXIFENE; CONJUGATED ESTROGEN; OSTEOCALCIN; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL THROMBOPHLEBITIS; VAGINA ATROPHY; VENOUS THROMBOEMBOLISM;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE DENSITY; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HIP JOINT; HUMANS; INDOLES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 69049083661     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.093     Document Type: Article

References (19)

1. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 276 (1996) 1389-1396
2. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 287 (2002) 2668-2676
3. Lindsay R., Gallagher J.C., Kleerekoper M., and Pickar J.H. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 16 (2005) 372-379
4. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. J Am Med Assoc 291 (2004) 1701-1712
5. Jackson R.D., Wactawski-Wende J., LaCroix A.Z., Pettinger M., Yood R.A., Watts N.B., et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 21 (2006) 817-828
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
7. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J Am Med Assoc 290 (2003) 1729-1738
8. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
9. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
10. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282 (1999) 637-645
11. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13 (1998) 1747-1754
12. Komm B.S., and Lyttle C.R. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 949 (2001) 317-326
13. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008
14. Ronkin S., Northington R., Baracat E., Nunes M.G., Archer D.F., Constantine G., et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105 (2005) 1397-1404
15. Miller P.D., Chines A.A., Christiansen C., Hoeck H.C., Kendler D.L., Lewiecki E.M., et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23 (2008) 525-535
16. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., De Villiers T.J., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 23 (2008) 1923-1934
17. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. London, 19 September 2002.
18. Pickar J.H., Yeh I.-T., Bachmann G., and Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92 (2009) 1018-1024
19. Lobo R.A., Pinkerton J.V., Gass M.L.S., Dorin M.H., Ronkin S., Pickar J.H., et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92 (2009) 1025-1038